Vincerx Pharma Q1 2024 net loss $12.4M ($0.58/sh); cash $5.1M plus $17.8M financing through 2024

Vincerx Pharma, Inc.

2024-Q1 EPS reported -$0.58

Cash $5.1M at Mar 31, 2024; April financing of ~$17.8M extends runway through 2024.
Net loss $12.4M ($0.58/sh) vs $14.6M ($0.69/sh) in Q1 2023; R&D spend $4.6M down from $10.9M.
VIP943 Phase 1 in fourth cohort; no dose-limiting toxicities in 11 pts; preliminary PK shows minimal circulating payload.
Enitociclib NIH combo study: four PRs in PTCL and one PR in tFL monotherapy; 63 pts enrolled overall.
VIP236 Phase 1 signs of tumor reduction and improved safety profile; updated data expected by end of Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vincerx Pharma, Inc. reported financial results for first quarter of 2024.

Period: first quarter of 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Vincerx Pharma, Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-138272

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.